Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Deininger

Showing results (41-50 of 79) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|October 21, 2014
Novel insights into the biology and treatment of chronic myeloproliferative neoplasmsTariq I Mughal, Tiziano Barbui, Omar Abdel-Wahab, et al.
Leukemia & Lymphoma|July 17, 2020
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study groupThoralf Lange, Christian Niederwieser, Arthur Gil, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Blood|May 31, 2002
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instabilityBrian J P Huntly, Anthony J Bench, Eric Delabesse, et al.
Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Ebiomedicine|November 26, 2019
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1<sup>T315I</sup>+ clones in TKI-resistant CMLMathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 24, 2005
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cellsMatthias Mayerhofer, Karl J Aichberger, Stefan Florian, et al.
Pageof 8

Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|October 21, 2014
Novel insights into the biology and treatment of chronic myeloproliferative neoplasmsTariq I Mughal, Tiziano Barbui, Omar Abdel-Wahab, et al.
Leukemia & Lymphoma|July 17, 2020
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study groupThoralf Lange, Christian Niederwieser, Arthur Gil, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Blood|May 31, 2002
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instabilityBrian J P Huntly, Anthony J Bench, Eric Delabesse, et al.
Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Ebiomedicine|November 26, 2019
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1<sup>T315I</sup>+ clones in TKI-resistant CMLMathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetMichele Baccarani, Jorge Cortes, Fabrizio Pane, et al.
Leukemia|March 31, 2021
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemiaGregor Eisenwort, Irina Sadovnik, Alexandra Keller, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 24, 2005
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cellsMatthias Mayerhofer, Karl J Aichberger, Stefan Florian, et al.
Pageof 8